Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

Pump housing and impeller design. (A): (left) Axial flow pump: HeartMate II LVAD (taken from Figure 2 in the HeartMate II left ventricular assist system instructions for use). (B) (right) Centrifugal flow pump: HeartWare assist device (taken from Figure 2 in the HeartWare assist device patient manual).
News | Heart Failure
Study Finds that Concurrent Tricuspid Valve Surgery and Left Ventricular Assist Device Implantation do not Appear to Lower the Incidence of Right Heart Failure

May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left ...

Home May 16, 2022
Home
Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData
News | Pharmaceuticals
Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
The Neurescue device is an FDA-approved device currently in use for patients with severe bleeding which will now be used in a new study to help increase survival rate for those who experience in-hospital cardiac arrests
News | Sudden Cardiac Arrest
MemorialCare Long Beach Medical Center Only Site in Nation to Offer ARISE-Study – New Experimental Treatment for In-Hospital Cardiac Arrest

May 13, 2022 — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only ...

Home May 13, 2022
Home
The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.
Feature | Cardiogenic Shock
Cardiogenic Shock Market Outlook

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

Home May 12, 2022
Home
NIH-funded study explains factors linked to increased risk for heart attack or stroke among women who have pregnancy problems related to high blood pressure
News | Womens Cardiovascular Health
Hypertensive Pregnancy Disorders Linked to Future Cardiac Events

May 11, 2022 — Women who experienced complications related to developing high blood pressure, or hypertension, during ...

Home May 11, 2022
Home
A microscopy picture of muscle cells in a normal heart (left) and muscle cells in a heart of a patient with hypertrophic cardiomyopathy (right). The black areas are single muscle cells. The muscle cells of the hypertrophic cardiomyopathy patient are bigger, and there is more space in between the cells (green), which is filled with scar tissues in the case of patients with hypertrophic cardiomyopathy. The blue indicates where the DNA of the cells can be found. Image courtesy of Anne de Leeuw, copyright Hubre
News | Cardiovascular Clinical Studies
Single Cell RNA Sequencing Uncovers New Mechanisms of Heart Disease

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Back on track after its in-person hiatus, ACC22 stressed industry resilience, and featured practice-changing science and innovations
Feature | ACC | By Melinda Taschetta-Millane
ACC22: Transforming Cardiovascular Care

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
Iocyte AMI-3 Trial to assess effectiveness and safety of FDY-5301 in improving outcomes for anterior STEMI patients undergoing primary PCI
News | STEMI
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

May 10, 2022 — Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 st ...

Home May 10, 2022
Home
Heart failure presents differently in women and men – discover the latest evidence and its impact on management at Heart Failure 2022, a scientific congress of the European Society of Cardiology (ESC).
News | ESC
Improving Outcomes for all Patients with Heart Failure

May 9, 2022 — Heart failure presents differently in women and men – discover the latest evidence and its impact on ...

Home May 09, 2022
Home
Primary tabs View(active tab) Edit Delete Revisions Entityqueue Devel Open configuration options Open configuration options Videos | Venous Therapies | June 27, 2017 VIDEO: How the Ekos Thrombolytic Technology Works to Dissolve Clots Open Related Chest Pain Imaging Content: configuration options Venous Thrombolytic System Demonstration Play Mute Remaining Time -3:23 Picture-in-Picture Fullscreen This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat dee
Feature | Cardiovascular Business
Top 10 Cardiology Videos on DAIC for April

Here are the top 10 performing videos on the Diagnostic and Interventional Cardiology (DAIC) website during the month of ...

Home May 09, 2022
Home
Heart failure patients implanted with Barostim can now receive conditional MRI scans
News | Magnetic Resonance Imaging (MRI)
CVRx Receives MR-conditional Labeling Approval for its Barostim Heart Failure System

May 9, 2022 — CVRx, Inc., developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of ...

Home May 09, 2022
Home
The trends of an increased interest in RPM and potential cost savings have inspired companies to participate in this slowly evolving paradigm shift and improve technology
Feature | Patient Monitors | By Amit Shah, MD, MSCR
Use and Benefits of RPM in a Clinical Setting

I work at Emory University in a multidisciplinary group that is employing medical technologies to improve our ...

Home May 05, 2022
Home
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction
News | Cardiovascular Clinical Studies
FARXIGA Met Primary Endpoint in DELIVER Phase III Trial

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
Woman experiencing chest pains
News | Sudden Cardiac Arrest
Surprising Risk Factors may Predict Heart Attacks in Young Women

May 5, 2022 – A new Yale-led study has for the first time identified which risk factors are more likely to trigger a ...

Home May 05, 2022
Home
Blood cells travelling in vessel
News | Heart Failure
Study Reveals how Blood Vessels use “Short Cuts” to Control the Cardiovascular System

May 5, 2022 – Cardiovascular disease is a group of conditions that can arise from a lack of physical activity, poor diet ...

Home May 05, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now